![Ашық рұқсат](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Рұқсат жабық](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Рұқсат жабық](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
№ 16 (2017)
- Жылы: 2017
- Мақалалар: 13
- URL: https://journals.eco-vector.com/2073-4034/issue/view/7055
Articles
NEWS OF MEDICINE
Pharmateca. 2017;(16):4-5
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Fixed-dose combinations in the therapy of type 2 diabetes mellitus: the way to achieving good glycemic control
Аннотация
The article presents an overview of modern approaches to the treatment of type 2 diabetes mellitus (DM2). The algorithm for the choice of hypoglycemic therapy according to the Russian Algorithm of specialized care for diabetic patients is discussed in detail. It is noted that according to the accumulated modern clinical experience, hypoglicemic monotherapy is usually effective in the first few years of the disease, but it is necessary to use combinations of various hypoglycemic agents in order to achieve and maintain the target blood glucose levels in most DM2 cases. It was concluded that modern fixed-dose combinations of hypoglycemic agents are an integral part of the DM2 pharmacotherapy.
Pharmateca. 2017;(16):6-12
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Increasing the dose of somatostatin analogues of in patients with active form of acromegaly: literature review and prospects for application
Аннотация
The article presents the data of foreign studies on the effectiveness and safety of escalation of dose of somatostatin analogues in patients with active form of acromegaly, who received standard doses of drugs. Increase in the dose of lanreotide allows achieving biochemical control in 27.6% of patients with previously uncontrolled acromegaly. Moreover, the drug has a favorable safety profile, and dose escalation does not adversely affect carbohydrate metabolism.
Pharmateca. 2017;(16):13-16
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Polymorbidity and modern medicine
Аннотация
The review article discusses the problem of polymorbidity through the example of metabolic syndrome. The data of recent years on the features of the combination of components of the metabolic syndrome with diseases of the cardiovascular system, respiratory organs, gout, thyroid pathology, etc. are presented.
Pharmateca. 2017;(16):17-20
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Diabetic distal polyneuropathy: the principles of diagnostics and therapy
Аннотация
The article discusses the clinical manifestations of diabetic distal polyneuropathy (DPN), the diagnosis of this complication, and the principles of therapy. Particular attention is paid to the treatment of DPN with pregabalin (Lyrica). The review of studies on the efficacy and safety of the use of pregabalin in diabetic patients with DPN is presented. Indication for the prescription of pregabalin includes the presence of characteristic symptoms of DPN. The initial dosage is 150 mg/day with a dose titration every 7 days, if necessary. In general, the drug is well tolerated, the side effects are associated with the mechanism of its action, and are transient, as a rule. The drug can be taken for a long time without reducing its effectiveness.
Pharmateca. 2017;(16):21-25
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
The use of insulin glargine 300 lU/ml (Toujeo SoloStar®) in real clinical practice
Аннотация
The article presents the results of clinical studies, including real-world data trials, on a new analogue of long-acting insulin glargine 300 IU/ml (Toujeo SoloStar®) in patients with type 2 diabetes mellitus. Increase in glargine concentration per unit volume with the formation of a small-volume subcutaneous depot led to a change in the pharmacokinetic properties of the drug: glargine 300 IU/ml compared with glargine 100 IU/ml is more slowly released from the subcutaneous fat depot, which provides more regular and long-acting effect. That led to a change in properties of the drug, which is clinically manifested in the form of achieving comparable glycemic control with less risk of hypoglycemia and less pronounced influence on body weight compared with insulin glargine 100 U/ml.
Pharmateca. 2017;(16):26-30
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Effect of SGLT-2 inhibitors on cardiovascular outcomes: review of results of CVD-REAL trial
Аннотация
The article presents a review of the results of real-world international retrospective cohort trial, CVD-REAL, comparing the efficacy of various of sodium-glucose linked transporter-2 (SGLT-2) inhibitors with other antidiabetic drugs in regard to cardiovascular outcomes in patients with type 2 diabetes mellitus (DM2). It is noted that this study supplements the already available results of randomized clinical trials, and indicates the potential of early prescription of SGLT-2 inhibitors for DM2 patients. Studies with a longer follow-up period are required to confirm the long-term and persistent effects of these drugs.
Pharmateca. 2017;(16):31-37
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Advantages of switch to premixed insulin degludec/aspart in patients with type 2 diabetes mellitus who have not achieved an optimal control with previous insulin therapy
Аннотация
Insulin degludec/aspart (IDeg/Asp) is the first soluble combination of the ultralong-acting human insulin analogue degludec (70%) and the fast-acting prandial human insulin analogue aspart (30%) in one injection. The unique pharmacodynamic profile of IDeg/Asp provides a stable effect of basal insulin (>24 hours), as well as effective prandial control, which does not affect on the basal effect. In patients with type 2 diabetes mellitus, the use of IDeg/Asp once and twice a day provides effective glycemic control with a lower risk of overall and nocturnal hypoglycemia compared to conventional premix and basal-bolus insulin therapy. Furthermore, when required patients can flexible change the injection time of IDeg/Asp compared with the conventional premix insulins. In patients previously received insulin therapy, the switch to IDeg/Asp is a simple helpful choice of optimization and intensification of insulin therapy, which allows to maintain a more stable glucose level during the day, to achieve individual glycemic target without increasing the hypoglycemia risk and adverse weight gain, and also is a well-tolerated. These clinical advantages give possibility to recommend IDeg/Asp as a simple and safe strategy of insulin therapy, including in patients previously received insulin but did not achieve glycemic control.
Pharmateca. 2017;(16):38-45
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Disturbances of the autonomic innervation of the cardiovascular system and hemostasis: their role in the change of microcirculation in patients with type 2 diabetes mellitus
Аннотация
In the study including 260 women with type 2 diabetes mellitus, an assessment of changes in cardiovascular innervation, hemostasis, and clarification of their association with microcirculatory disturbances were performed. In most of these patients, the decrease in linear velocity of arteriolar blood flow and the violation of vascular reactivity were determined, which may be due to the presence of cardiovascular autonomic neuropathy and disorders in the hemostasis system towards hypoaggregation, intensifying against the background of severe decompensation of diabetes.
Pharmateca. 2017;(16):46-50
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Effectiveness of additional cardiotropic therapy in patients with symptoms of hypertherosis on the background of diffuse toxic goiter
Аннотация
The article presents the results of a 6-month prospective comparative evaluation of the efficacy of two treatment options for patients with signs of hyperthyroidism on the background of diffuse toxic goiter. First group received traditional therapy with thiamazole and ß-blocker, the second group additionally received an angiotensin-converting enzyme inhibitor and ethylmethylhydroxypyridine succinate. The additional efficacy of combined therapy with the use of these agents for correcting clinical manifestations of hyperthyroidism with a positive effect on the morphometric and hemodynamic parameters of the functioning of the cardiovascular system is shown. The authors give an overview of the literature data, justifying the need for study and correction of cardiovascular pathology against the background of traditional thyrotropic therapy in cases of hyperthyroidism.
Pharmateca. 2017;(16):51-57
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Features of urine microflora in diabetic patients
Аннотация
The article is devoted to the problem of contamination of urinary tract by mono- or mixed cultures of microorganisms in patients with diabetes mellitus (DM). 76 patients were examined, including 31 (40.79%) with DM1 and 45 (59.21%) with DM2. Diabetic nephropathy was diagnosed in 31 (40.79%) patients out of a total number of patients. Among all urine samples tested, only 8 (10.53%) were found to be sterile. 86 strains of opportunistic pathogens were isolated from 68 (89.47%) samples of the biomaterial. In DM1 patients, coagulase-negative staphylococci (32.25%) and enterococci (29.03%) were prevalent; in DM2 patients Enterobacteriaceae family representatives dominated (34.55%). The highest susceptibility to nitrofurans (nitrofurantoin) and carbapenems (imipenem, meropenem) was observed for all isolated microorganisms. Nitrofurantoin, imipenem, cefepime and ampicillin can be recommended as the drugs of choice for the treatment of urinary tract infections in diabetic patients.
Pharmateca. 2017;(16):58-61
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)
Amiodarone therapy and thyroid function
Аннотация
Due to the widespread use of amiodarone in clinical practice, it is necessary to remember its possible undesirable effects. Treatment with amiodarone can lead to impaired thyroid functional activity from minor changes to hypothyroidism or severe thyrotoxicosis (amiodarone -induced thyreopathy-AIT). The questions of pathogenesis, diagnosis and treatment of AIT are discussed. Particular attention is paid to the examination of the patient before starting therapy with amiodarone. The question of canceling or continuing treatment with amiodarone in AIT should be addressed individually for each patient collaboratively by a cardiologist and endocrinologist.
Pharmateca. 2017;(16):66-71
![pages](/img/style/pages.png)
![views](/img/style/views.png)
![](/img/style/loadingSmall.gif)